A phase III expansion study of Fovista administered with anti-VEGF therapy for the potential improvement of visual outcome for anti-VEGF treatment-resistant cases
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2019
Price : $35 *
At a glance
- Drugs Pegpleranib (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 05 Nov 2015 According to an Ophthotech media release, the company plans to report the interim results by the end of 2015.
- 05 Nov 2015 Status changed from planning to active, no longer recruiting, according to an OphthoTech Corporation media release.
- 23 Feb 2015 According to an Ophthotech Corporation media release, this trial is expected to begin in 2015.